Survodutide
GLP-1/GCG · s.c. · Boehringer Ingelheim / Zealand
Summary
- Also known as
- BI 456906
- Mechanism
- GLP-1/GCG
- Route
- s.c.
- Company
- Boehringer Ingelheim / Zealand
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 positive in obesity (SYNCHRONIZE-1, NEJM 2026) and T2D (SYNCHRONIZE-2, NEJM 2026); SYNCHRONIZE-CVOT showed CV safety (non-inferior to placebo, Lancet Nov 2026) verify
- Next milestone
- MASH phase 3 (LIVERAGE)
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 (SYNCHRONIZE-1); regulatory submissions in preparation (Boehringer Ingelheim, November 2026) | SYNCHRONIZE-1; Boehringer Ingelheim release, 9 Nov 2026 |
| T2D | 3 positive phase 3 | Positive phase 3 (SYNCHRONIZE-2, NEJM/EASD 2026) | SYNCHRONIZE-2 (Oct 2026) |
| CV outcomes | 3 positive phase 3 | SYNCHRONIZE-CVOT (Lancet, Nov 2026): CV safety shown — non-inferior to placebo for five-point MACE, HR 0.89 (0.67–1.18); not designed or powered for superiority | SYNCHRONIZE-CVOT (Lancet 2026); NCT06077864 |
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 2 phase 3 ongoing | Phase 2 positive; phase 3 (LIVERAGE) ongoing | Phase 2 MASH |
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Survodutide phase 2 (obesity) | survodutide 4.8 mg | obesity | 46 | 387 | −18.7 % vs −2.3 % Δ −16.4 pp | −14.9 % vs −2.8 % Δ −12.1 pp | — | 29.0 vs 4.0 | 39.0 vs 40.3 | 64.0 vs 20.0 | 35.0 vs 5.0 | 5.0 vs 7.0 | −8.6 vs −2.5 | verified |
| SYNCHRONIZE-1 | survodutide 3.6 mg | obesity | 76 | 241 | −15.3 % vs −3.2 % Δ −12.1 pp | −12.2 % vs −5.4 % Δ −6.8 pp | −0.2 vs +0.0 | 23.7 vs 5.4 | 35.3 vs 40.1 | 61.0 vs 17.4 | 40.7 vs 6.2 | 8.3 vs 6.2 | −6.7 vs −5.9 | verified |
| SYNCHRONIZE-1 | survodutide 6.0 mg | obesity | 76 | 242 | −16.6 % vs −3.2 % Δ −13.4 pp | −13.0 % vs −5.4 % Δ −7.6 pp | −0.2 vs +0.0 | 24.8 vs 5.4 | 34.3 vs 40.1 | 64.9 vs 17.4 | 44.6 vs 6.2 | 8.3 vs 6.2 | −5.4 vs −5.9 | verified |
| SYNCHRONIZE-2 (obesity + T2D) | survodutide 3.6 mg | t2d | 76 | — | −10.4 % vs −3.1 % Δ −7.3 pp | −8.2 % vs −3.9 % Δ −4.3 pp | −0.9 vs −0.2 | 26.4 vs 8.8 | 36.0 vs 30.7 | 47.6 vs 11.2 | 34.4 vs 5.6 | 9.2 vs 10.8 | −3.5 vs −2.7 | verified |
| SYNCHRONIZE-2 (obesity + T2D) | survodutide 6.0 mg | t2d | 76 | — | −13.1 % vs −3.1 % Δ −10.0 pp | −9.8 % vs −3.9 % Δ −5.9 pp | −0.8 vs −0.2 | 25.9 vs 8.8 | 34.7 vs 30.7 | 57.4 vs 11.2 | 39.0 vs 5.6 | 8.4 vs 10.8 | −3.7 vs −2.7 | verified |
| SYNCHRONIZE-CVOT | survodutide 3.6 mg | obesity | 72 | — | — | −9.3 % vs −2.4 % Δ −6.9 pp | — | 28.2 vs 11.1 | 44.0 vs 41.0 | 48.0 vs 12.1 | 31.7 vs 4.8 | 22.5 vs 23.9 | −4.3 vs −1.7 | verified |
| SYNCHRONIZE-CVOT | survodutide 6.0 mg | obesity | 72 | — | — | −9.7 % vs −2.4 % Δ −7.3 pp | — | 29.1 vs 11.1 | 43.4 vs 41.0 | 49.0 vs 12.1 | 34.0 vs 4.8 | 20.8 vs 23.9 | −4.9 vs −1.7 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- survodutide 3.6 mg: Any discontinuation = 100 − % still on drug at week 76.
- survodutide 3.6 mg: Any discontinuation = 100 − % still on drug at week 76.
- survodutide 3.6 mg: CV outcomes trial in a mixed population: obesity at increased CV risk, 52.7 % with type 2 diabetes, 52.8 % coronary artery disease, 10.9 % heart failure. Weight and SBP at week 72 (treatment-regimen); safety over the treatment period (median exposure 19 months). Not used in Map 6 (indirect comparisons combine only trials of the same population).
- survodutide 6.0 mg: CV outcomes trial in a mixed population: obesity at increased CV risk, 52.7 % with type 2 diabetes, 52.8 % coronary artery disease, 10.9 % heart failure. Weight and SBP at week 72 (treatment-regimen); safety over the treatment period (median exposure 19 months). Not used in Map 6 (indirect comparisons combine only trials of the same population).
Verbatim quotes from the source (58)
- survodutide 4.8 mg · weight_eff · Results, paragraph 2 and Table 2
to -18-7% (-20-8 to -16-6; survodutide 4-8 mg) when participants were analysed according to the actual treatment
- survodutide 4.8 mg · weight_tp · Results, paragraph 2; Abstract; Table 2
-14-9% (-16-9 to -13-0; survodutide 4-8 mg) versus -2-8% (-4-9 to -0-7) for placebo
- survodutide 4.8 mg · ae_dc · Results, adverse events paragraph and Table 3
4-8 mg, 22 [29%] of 77; 0-6 mg, 15 [20%] of 7; 2-4 mg, 20 [26%] of 78; 3-6 mg, 19 [25%] of 77
- survodutide 4.8 mg · nausea · Table 3
Nausea” 15 (20%) 26 (34%) 51 (65%) 48 (62%) 49 (64%) 174 (56%)
- survodutide 4.8 mg · vomiting · Table 3
Vomiting" 4(5%) 7(9%) 23 (30%) 26 (34%) 27 (35%) 83 27%)
- survodutide 4.8 mg · sae · Table 3
Serioust 5(7%) 10%) 2%) 6 (8%) 4 (5%) 33 (4%)
- survodutide 4.8 mg · sbp · Table 2, planned treatment
Systolic blood 62 “81 -87 -86 25 37 56 62 62
- survodutide 4.8 mg · disc_any · Figure 1 (trial profile)
20 prematurely stopped 22 prematurely stopped 18 prematurelystopped 18 prematurely stopped 22 prematurely stopped
- survodutide 3.6 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
−15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
- survodutide 3.6 mg · weight_tp · Table 1
Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
- survodutide 3.6 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
- survodutide 3.6 mg · nausea · Table 3
Nausea 147 (61.0) 157 (64.9) 42 (17.4)
- survodutide 3.6 mg · vomiting · Table 3
Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
- survodutide 3.6 mg · sae · Table 3
Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
- survodutide 3.6 mg · hba1c · Table 2
Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
- survodutide 3.6 mg · sbp · Table 1
Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
- survodutide 3.6 mg · disc_any · Results, participants paragraph
63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
- survodutide 6.0 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
−15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
- survodutide 6.0 mg · weight_tp · Table 1
Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
- survodutide 6.0 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
- survodutide 6.0 mg · nausea · Table 3
Nausea 147 (61.0) 157 (64.9) 42 (17.4)
- survodutide 6.0 mg · vomiting · Table 3
Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
- survodutide 6.0 mg · sae · Table 3
Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
- survodutide 6.0 mg · hba1c · Table 2
Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
- survodutide 6.0 mg · sbp · Table 1
Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
- survodutide 6.0 mg · disc_any · Results, participants paragraph
63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
- survodutide 3.6 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
- survodutide 3.6 mg · weight_tp · Table 2
Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
- survodutide 3.6 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
- survodutide 3.6 mg · nausea · Table 3
Nausea 119 (47.6) 144 (57.4) 28 (11.2)
- survodutide 3.6 mg · vomiting · Table 3
Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
- survodutide 3.6 mg · sae · Table 3
Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
- survodutide 3.6 mg · hba1c · Table 2
Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
- survodutide 3.6 mg · sbp · Table 2
Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
- survodutide 3.6 mg · disc_any · Results, Participants (Fig. S2, Table S3)
and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
- survodutide 6.0 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
- survodutide 6.0 mg · weight_tp · Table 2
Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
- survodutide 6.0 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
- survodutide 6.0 mg · nausea · Table 3
Nausea 119 (47.6) 144 (57.4) 28 (11.2)
- survodutide 6.0 mg · vomiting · Table 3
Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
- survodutide 6.0 mg · sae · Table 3
Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
- survodutide 6.0 mg · hba1c · Table 2
Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
- survodutide 6.0 mg · sbp · Table 2
Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
- survodutide 6.0 mg · disc_any · Results, Participants (Fig. S2, Table S3)
and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
- survodutide 3.6 mg · weight_tp · Table 3
Mean change in bodyweight −9·3% −9·7% −2·4%
- survodutide 3.6 mg · ae_dc · Table 4
Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
- survodutide 3.6 mg · disc_any · Results, paragraph 2 (also Figure 1)
807 (44·0%) participants in
- survodutide 3.6 mg · nausea · Table 4
Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
- survodutide 3.6 mg · vomiting · Table 4
Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
- survodutide 3.6 mg · sae · Table 4
Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
- survodutide 3.6 mg · sbp · Table 2
Survodutide 3·6 mg: absolute change 1836 −4·29 1836 −1·72
- survodutide 6.0 mg · weight_tp · Table 3
Mean change in bodyweight −9·3% −9·7% −2·4%
- survodutide 6.0 mg · ae_dc · Table 4
Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
- survodutide 6.0 mg · disc_any · Results, paragraph 2 (also Figure 1)
796 (43·4%) in the
- survodutide 6.0 mg · nausea · Table 4
Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
- survodutide 6.0 mg · vomiting · Table 4
Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
- survodutide 6.0 mg · sae · Table 4
Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
- survodutide 6.0 mg · sbp · Table 2
Survodutide 6·0 mg: absolute change 1835 −4·89 1836 −1·72
Outcome trials
Cardiovascular and kidney outcome trials
SYNCHRONIZE-CVOT survodutide 3.6 or 6.0 mg once weekly (pooled) vs placebo · Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD) · n = 5530 · 2026 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| Expanded MACE primary Primary endpoint: five-point MACE = time to first CV death, non-fatal stroke, non-fatal MI, ischaemia-related coronary revascularisation, or heart failure event (HHF, ED visit, urgent care visit or urgent outpatient HF visit); non-inferiority margin 1.65 | 0.89 | 0.67–1.18 | 136 vs 76 | verified |
| 3-point MACE Key secondary: three-point MACE = CV death, non-fatal stroke, non-fatal MI (non-inferiority vs placebo) | 0.84 | 0.60–1.18 | 88 vs 52 | verified |
| 4-point MACE Four-point MACE as defined by the trial = CV death, non-fatal stroke, non-fatal MI, or ischaemia-related coronary revascularisation | 0.93 | 0.67–1.29 | 103 vs 55 | verified |
| Cardiovascular death Adjudicated death from cardiovascular causes (component of primary endpoint) | 1.05 | 0.49–2.23 | 21 vs 10 | verified |
| All-cause death All-cause mortality | 1.20 | 0.73–1.97 | 53 vs 22 | verified |
| Myocardial infarction Adjudicated non-fatal myocardial infarction — non-fatal events only | 0.99 | 0.60–1.64 | 46 vs 23 | verified |
| Stroke Adjudicated non-fatal stroke — non-fatal events only | 0.72 | 0.41–1.27 | 29 vs 20 | verified |
| Heart failure event Heart failure event, broader than hospitalisation alone: hospitalisation, emergency department visit, urgent care visit or urgent outpatient heart failure visit (adjudicated). CV death or hospitalisation for HF: HR 0.86 (0.55–1.35). | 0.76 | 0.46–1.25 | 40 vs 26 | verified |
| CV death or worsening HF First occurrence of adjudicated CV death or adjudicated heart failure event (HF event incl. HHF, ED/urgent visits) | 0.80 | 0.52–1.22 | 56 vs 35 | verified |
| Coronary revascularisation Adjudicated ischaemia-related coronary revascularisation | 2.49 | 0.85–7.30 | 20 vs 4 | verified |
| New-onset diabetes Onset of (protocol-defined) type 2 diabetes in participants without type 2 diabetes at baseline | 0.28 | 0.16–0.50 | 18 vs 32 | verified |
Verbatim quotes (11)
- Expanded MACE · Table 2, primary composite endpoint row, p 8
Pooled survodutide: primary composite 136 (3·7%) 2·15 76 (4·1%) 2·42 0·89 ·· ·· <0·0001 endpoint (five-point MACE)* (non- (0·67 to 1·18)†
- 3-point MACE · Table 2, key secondary endpoints, p 8
Pooled survodutide: three-point 88 (2·4%) 1·38 52 (2·8%) 1·64 0·84 ·· ·· <0·0001 MACE (non-inferiority vs placebo)‡ (0·60 to 1·18)
- 4-point MACE · Table 2 (continued), other secondary endpoints, p 9
First occurrence of any adjudicated 103 (2·8%) 1·62 55 (3·0%) 1·74 0·93 ·· ·· NA component of four-point MACE§ (0·67 to 1·29)
- Cardiovascular death · Table 2, primary endpoint components, p 8
Death from cardiovascular causes 21 (0·6%) 0·32 10 (0·5%) 0·30 1·05 ·· ·· NA (0·49 to 2·23)
- All-cause death · Table 2 (continued), other secondary endpoints, p 9
All-cause mortality 53 (1·4%) 0·80 22 (1·2%) 0·67 1·20 ·· ·· NA (0·73 to 1·97)
- Myocardial infarction · Table 2, primary endpoint components, p 8
Non-fatal myocardial infarction 46 (1·3%) 0·72 23 (1·3%) 0·72 0·99 ·· ·· NA (0·60 to 1·64)
- Stroke · Table 2, primary endpoint components, p 8
Non-fatal stroke 29 (0·8%) 0·45 20 (1·1%) 0·63 0·72 ·· ·· NA (0·41 to 1·27)
- Heart failure event · Table 2, primary endpoint components, p 8
Heart failure event† 40 (1·1%) 0·63 26 (1·4%) 0·82 0·76 ·· ·· NA (0·46 to 1·25)
- CV death or worsening HF · Table 2 (continued), other secondary endpoints, p 9
First occurrence of adjudicated death 56 (1·5%) 0·88 35 (1·9%) 1·10 0·80 ·· ·· NA from cardiovascular causes or (0·52 to 1·22)
- Coronary revascularisation · Table 2, primary endpoint components, p 8
Ischaemia-related coronary 20 (0·5%) 0·31 4 (0·2%) 0·12 2·49 ·· ·· NA revascularisation (0·85 to 7·30)
- New-onset diabetes · Table 2 (continued), other secondary endpoints, p 9
Onset of type 2 diabetes in 18 (1·1%) 0·60 32 (3·6%) 2·10 0·28 ·· ·· NA participants without type 2 diabetes (0·16 to 0·50)
Other indications
Survodutide phase 2 MASH Survodutide · MASH F1–F3 · 48 weeks · n = 293 seed
Histological improvement of MASH 83 % vs 18 %
Registered trials (14)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| ELEVATE-LIVER ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease | HFpEF | Phase 3 | not yet recruiting | 2026-11 → 2029-04 | 600 | not yet recruiting | NCT07850063 |
| SYNCHRONIZE-START SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | Phase 3 | not yet recruiting | 2026-11 → 2029-11 | 350 | not yet recruiting | NCT07855900 |
| SYNCHRONIZE-HERA SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight | Obesity | Phase 3 | not yet recruiting | 2026-10 → 2028-07 | 600 | not yet recruiting | NCT07850050 |
| NCT07754461 A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | T2D | Phase 3 | recruiting | 2026-08 → 2028-01 | 600 | recruiting | NCT07754461 |
| ARTIST-CKD Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease | CKD | Phase 2 | not yet recruiting | 2026-03 → 2027-11 | 120 | not yet recruiting | NCT07206290 |
| LIVERAGE - Cirrhosis LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | MASH | Phase 3 | recruiting | 2024-11 → 2029-06 | 1590 | recruiting | NCT06632457 |
| LIVERAGE LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | MASH | Phase 3 | recruiting | 2024-10 → 2031-12 | 1800 | recruiting | NCT06632444 |
| SYNCHRONIZE-MASLD A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) | MASH | Phase 3 | completed | 2024-04 → 2025-10 | 218 | Completed; results not in the atlas yet | NCT06309992 |
| NCT06214741 · China A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight | Obesity | Phase 3 | completed | 2024-02 → 2025-07 | 307 | Completed; results not in the atlas yet | NCT06214741 |
| SYNCHRONIZEJP A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease | Obesity | Phase 3 | completed | 2024-01 → 2025-12 | 274 | Completed; results not in the atlas yet | NCT06176365 |
| SYNCHRONIZE-CVOT A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | CV outcomes | Phase 3 | completed | 2023-11 → 2026-06 | 5530 | 5-point MACE HR 0.89 (0.67–1.18) vs placebo: non-inferior (CV safety) | NCT06077864 |
| SYNCHRONIZE-1 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | Phase 3 | completed | 2023-11 → 2025-12 | 726 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06066515 |
| SYNCHRONIZE-2 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Obesity | Phase 3 | completed | 2023-11 → 2025-12 | 755 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06066528 |
| Survodutide phase 2 MASH A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) | MASH | Phase 2 | completed | 2021-04 → 2023-11 | 295 | MASH improvement 83 % vs 18 % (phase 2) | NCT04771273 |
Primary sources
- Boehringer Ingelheim. A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight. ClinicalTrials.gov identifier NCT04667377. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04667377
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID: 38330987.
- le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026;395(8):776-787. PMID: 42253238.
- Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. 2026. PMID: 42820639.
- Bozkurt B, le Roux CW, Wharton S, Butt JH, Startseva E, Sumin M, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Nov 9. doi:10.1016/S0140-6736(26)02140-9. Available from: https://doi.org/10.1016/S0140-6736(26)02140-9
- Boehringer Ingelheim. A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD. ClinicalTrials.gov identifier NCT06077864. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06077864
- Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PMID: 38847460.
How to cite this page
Cite the primary publication for any single result; every value above links to it.